Torrent Pharmaceuticals Ltd.
NSE: TORNTPHARM · Healthcare
Strong Q1 FY27 results (54.6% sales growth, 33.8% EBITDA margin) and bullish EMA alignment validate JB Pharma integration; elevated 78.75x…
Q1 FY27 delivered 54.6% sales growth to ₹48.35 billion with 33.8% EBITDA margin, confirming JB Pharma integration success and India/Brazil organic momentum (15% and 30% YoY respectively).
Stock trades at extreme 78.75x TTM P/E with only one quarter of post-integration data; weak volume (0.91x 20-day average) and elevated leverage (2.3x net debt/EBITDA) signal execution risk.
Free: 5 Forecasts and 5 Debates a month. Log in with your mobile number.
-
Bullish 28 Sep 2026 → now Scores 28 Oct 2026₹4,869.00 → ₹4,869.00 0.0%
Every verdict and forecast here is dated and scored when it matures — right or wrong. The first scored results publish a month after launch.
How we score →
Bullzeye Financial